skip to main content


Evgen Pharma was founded in 2007 by Dr Stephen Franklin in collaboration with two venture capital investors, Enterprise Ventures and Imprimatur Capital, with the objective of securing intellectual property rights relating to natural products with potential in healthcare.

Evgen Pharma Image : History

Following seed capital investment, Stephen began a detailed search during which he identified and reviewed technologies from academic institutes and corporates in North America, Europe and Australasia. In 2009, Barry Clare joined Evgen Pharma as Chairman at the time that Stephen had identified the opportunity to acquire intellectual property rights to commercialise sulforaphane, a naturally occurring anti-cancer agent of botanical origin.

In 2010, the decision was taken to focus on intellectual property secured under licence from PharmAgra Labs Inc, a US chemical synthesis company that had discovered a method for synthesising and stabilising sulforaphane in a sugar lattice. The company branded the stabilised sulforaphane technology, Sulforadex®, and began building its pharmaceutical development capability.

In 2011, the team was further strengthened and  Evgen Pharma  broadened its shareholder base through a Series A funding round, preparing the company to begin preclinical and clinical development. By mid-2014, the company had advanced lead product SFX-01 through preclinical safety and toxicology and had completed two Phase I trials. Whilst this work was underway, Evgen Pharma examined further potential indications for SFX-01  both as an anti-cancer agent and as an anti-inflammatory agent.

Evgen Pharma joined the AIM market of the London Stock Exchange in October 2015 and subsequently acquired the world-wide rights to a series of novel sulforaphane analogues from the Spanish Research Council and the University of Seville.

In March 2019, Evgen Pharma announced positive results from the open-label Phase II trial of SFX-01 in patients with oestrogen-positive metastatic breast cancer that had become resistant to all prior lines of hormone therapy.